Studying Biomarkers in Samples From Younger Patients With Kidney Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01642095|
Recruitment Status : Withdrawn
First Posted : July 17, 2012
Last Update Posted : February 17, 2014
|Condition or disease||Intervention/treatment|
|Clear Cell Renal Cell Carcinoma Congenital Mesoblastic Nephroma Rhabdoid Tumor of the Kidney Wilms Tumor and Other Childhood Kidney Tumors||Other: laboratory biomarker analysis|
I. To determine whether focal adhesion kinase (FAK) is expressed and if FAK is phosphorylated in pediatric renal tumors.
Archived tumor tissue samples are analyzed for FAK expression by immunohistochemistry (IHC). IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Focal Adhesion Kinase Expression in Pediatric Renal Tumors|
|Study Start Date :||August 2012|
|Actual Primary Completion Date :||September 2012|
Basic science (FAK expression)
Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
Other: laboratory biomarker analysis
- FAK expression in pediatric renal tumors [ Time Frame: Baseline ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642095
|Principal Investigator:||Elizabeth Beierle, MD||Children's Oncology Group|